After CAR‐T cell therapy, patients with CRS could exhibit liver and kidney dysfunction, as well as delayed hematopoietic recovery, characterized by elevated ALT, AST, BUN and Cr, and delayed peripheral blood recovery,13 but the mechanism remains unclear. The gene discussed is GPT; the disease is congenital rubella syndrome.